CTC Isolation from a Whole Blood Sample: A Method to Obtain CTCs from Murine Colorectal Cancer Model
JoVE Encyclopedia of Experiments
Cancer Research
0 views • 3:50 min • April 30th, 2023
Loading...
Overview
This article discusses the isolation and identification of circulating tumor cells (CTCs) from the blood of a colorectal cancer mouse model. CTCs are crucial for understanding cancer progression as they indicate tumor spread.
Key Study Components
Area of Science
- Oncology
- Cell Biology
- Translational Research
Background
- Circulating tumor cells (CTCs) originate from primary tumors and enter the bloodstream.
- CTCs can survive in circulation and are detectable in cancer patients' blood.
- Identifying CTCs helps in assessing tumor metastasis.
- EpCAM is a marker expressed by CTCs, aiding in their identification.
Purpose of Study
- To isolate and identify EpCAM-expressing CTCs from the blood of colorectal cancer mice.
- To develop a protocol for downstream analysis of CTCs.
- To enhance understanding of cancer progression through CTC analysis.
Methods Used
- Blood collection from anesthetized colorectal cancer mouse model via cardiac puncture.
- Centrifugation of blood samples to separate components.
- Use of anti-EpCAM antibodies to label CTCs for identification.
- Microscopic examination and micromanipulation for cell selection.
Main Results
- Successful isolation of peripheral blood mononuclear cells (PBMC) from blood samples.
- Identification of EpCAM-positive CTCs using fluorescence microscopy.
- Establishment of a reliable method for CTC collection and analysis.
- Potential for further downstream applications in cancer research.
Conclusions
- The protocol effectively isolates CTCs for analysis.
- CTCs can serve as biomarkers for cancer progression.
- This method can be applied to other cancer types for similar studies.
Frequently Asked Questions
What are circulating tumor cells (CTCs)?
CTCs are cancer cells that detach from the primary tumor and circulate in the bloodstream.
Why is it important to isolate CTCs?
Isolating CTCs helps in understanding tumor metastasis and progression.
What is the role of EpCAM in this study?
EpCAM is a marker used to identify CTCs in blood samples.
How are CTCs collected from blood samples?
CTCs are collected through centrifugation and selective labeling with antibodies.
What are the potential applications of this research?
This research can lead to advancements in cancer diagnostics and treatment monitoring.
Executive Industry Relevance
Isolation of circulating tumor cells (CTCs) from whole blood in murine colorectal cancer models enables direct interrogation of metastatic potential and tumor cell dissemination. This workflow supports predictive confidence in preclinical oncology by providing access to rare cell populations for downstream molecular and phenotypic analysis. Integrating CTC isolation into discovery pipelines enhances mechanistic de-risking and informs translational biomarker strategies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct assessment of tumor cell dissemination and metastatic risk in preclinical models.
- Supports functional validation of epithelial markers such as EpCAM for target confidence.
- Facilitates mechanistic de-risking by isolating and characterizing rare circulating populations.
Screening & Assay Development
- Provides validated CTC populations for downstream assay development and compound screening.
- Standardizes CTC identification using anti-EpCAM labeling and fluorescence microscopy.
- Enables reproducible preparation of CTC samples for quantitative and comparative analyses.
Translational & Preclinical Research
- Aligns preclinical CTC isolation with translational biomarker discovery for metastasis monitoring.
- Supports continuity from in vivo tumor models to ex vivo cellular and molecular profiling.
- Informs risk-adjusted advancement decisions by linking CTC presence to disease progression.
Pipeline & Workflow Integration
This CTC isolation protocol fits within the preclinical discovery continuum, bridging in vivo tumor modeling and downstream molecular analysis.
- Discovery Biology: Enables hypothesis testing on tumor cell dissemination and metastatic mechanisms.
- Screening: Provides standardized, reproducible CTC samples for assay readiness and quantitative evaluation.
- Analytics: Delivers measurable outputs such as EpCAM positivity and CTC counts for condition comparison.
- Translational Research: Connects preclinical CTC findings to potential clinical biomarker strategies.
- Enterprise Reuse: Establishes a reusable workflow for CTC isolation across oncology models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in metastatic risk and target validation.
- Operational Value: Standardizes rare cell isolation and identification for reproducibility.
- Strategic Value: Supports informed go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of oncology assets based on CTC data.
Implementation Considerations
- Requires expertise in murine blood collection and rare cell handling.
- Needs access to fluorescence microscopy and micromanipulation tools.
- Demands cross-team standardization of antibody labeling and cell identification protocols.
- Adaptation may be needed for different tumor models or marker panels.
- Yield and purity depend on technical proficiency and model-specific variables.
Biopharma FAQs
Why does null hypothesis testing matter for CTC identification?
Null hypothesis testing ensures that observed EpCAM-positive cell counts reflect true CTC presence rather than background or nonspecific labeling, supporting robust target validation in preclinical models.
How does independent variable isolation fit CTC workflow design?
Isolating variables such as antibody specificity and centrifugation parameters allows teams to attribute CTC detection outcomes directly to biological differences, strengthening discovery-stage conclusions.
What do quantitative EpCAM-positive CTC measurements enable?
Quantitative measurement of EpCAM-positive CTCs enables comparative analysis across experimental groups, informing mechanistic studies and supporting translational biomarker development.
Why are replication requirements critical for CTC isolation studies?
Replication ensures that CTC isolation and identification are reproducible across samples and operators, facilitating cross-functional collaboration and reliable data integration in R&D pipelines.
Which statistical analysis capabilities are needed before CTC data implementation?
Statistical analysis must support comparison of CTC counts, assessment of detection thresholds, and validation of marker specificity to ensure data robustness before integration into decision-making workflows.
07:35
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Related Videos
0 Views
09:51
Immuno-fluorescent Labeling of Microtubules and Centrosomal Proteins in Ex Vivo Intestinal Tissue and 3D In Vitro Intestinal Organoids
Related Videos
0 Views
10:40
Single-Cell Resolution Three-Dimensional Imaging of Intact Organoids
Related Videos
0 Views
07:32
Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples
Related Videos
0 Views
04:05
CTC Immunofluorescence Assay : A Technique to Characterize Circulating Tumor Cells
Related Videos
0 Views
14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Related Videos
0 Views
05:22
Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
Related Videos
0 Views
06:19
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Related Videos
0 Views
10:54
Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol
Related Videos
0 Views
05:17
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
Related Videos
0 Views
Last updated: 11 July 2026